| Soda Tax Uncaps Fight Makers and sellers of soda and other sweet drinks have intensified a fight against proposed taxes on their products, as a growing number of cities and states are weighing the measures to help fill depleted coffers. online.wsj.com |
Medical Radiation a Growing Concern It's true that we get too much radiation, but not from sources we fret about—airport scanners, power lines, cell phones, microwaves. It's from too many medical tests. online.wsj.com |
Arena's Obesity Drug Likely to Pass FDA Panel With Flying Colors Rockford Coscia submits:This year a trio of obesity drugs has stormed onto the stage and they will soon face their respective FDA decisions. The trio consists of Vivus’ (VVUS) Qnexa, which was already voted down by an FDA panel, Arena’s (ARNA) Lorcaserin, and Orexigen’s (OREX) Contrave. Following Qnexa’s jilting by FDA panel, many investors piled into Arena as lorcaserin’s side effect profile appeared the most benign of the three. Lorcaserin faces its own FDA panel on September 16. While I’m guessing that multiple issues will be discussed – including potential off-label use with fentermine – one of the issues likely to be addressed is the potential of valvulopathy in long-term use of lorcaserin. There is very good reason to believe, however, that these concerns will be little more than a distraction on the way to lorcaserin’s approval.Complete Story » seekingalpha.com |
Preparing for Inspire Pharmaceutical's 2011 Phase 3 Catalyst Tony Pelz submits:As most everyone in the biotech space is focused on the events coming in September/October, it’s a good idea to scan for companies with longer term, yet largely ignored, future catalysts. One such company with an impending future catalyst is Inspire Pharmaceuticals (ISPH). Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases.(1) Inspire receives revenues through several product offerings targeting bacterial conjunctivitis, allergic conjunctivitis and dry eye. The referenced future catalyst involves their Phase 3 drug candidate Denufosol Tetrasodium, an inhalation solution for cystic fibrosis. According to the Company:Complete Story » seekingalpha.com |
Tracking Your Health Online Are online services the best way to manage medical records? They let you store all your health information in one place, and can serve as health aids. But entering data can be tedious, and some people have privacy concerns. An assessment of three of the most popular sites. online.wsj.com |